Art. -Nr.: HY-122218

JHU-083

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b⁺ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.38%
CAS. Nr.: 1998725-11-3
Formel: C₁₄H₂₄N₄O₄
Molecular Weight:312.36

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

JHU-083 Chemical Structure

CAS. Nr.: 1998725-11-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vivo
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vivo

JHU-083 (1.82 mg/kg; PO; every other day for 12 days) ameliorates social avoidance behavior and anhedonia-like behavior induced by CSDS^[1].
JHU-083 (1.82 mg/kg, PO) attenuates CSDS-induced increase in glutaminase activity in CD11b+ cells in the prefrontal cortex and hippocampus, but not in the cerebellum. JHU-083 treatment suppresses the CSDS-induced upregulation of IL-1β and TNF-α expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male 7-to 8-week-old C57BL/6J (C57) mice (25-30 g) with chronic social defeat stress (CSDS)^[1]
Dosage:

1.82 mg/kg
Administration:

PO; every other day for 12 days
Result:

Ameliorated social avoidance behavior and anhedonia-like behavior induced by CSDS.

Chemical Information

CAS. Nr. 1998725-11-3
Appearance Solid
Molecular Weight 312.36
Formel C₁₄H₂₄N₄O₄
Color Light yellow to yellow
SMILES

O=C(OCC)[C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C)C)N)=O
Versand

Shipping with dry ice.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (9)

All Cell Proliferation/Viability AssayWBIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

Nature

ZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expression. [Abstract]

2026 Apr;652(8111):1004-1015. PMID: 41639460

JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]

Cell numbers (normalized to control) in ZFTA–RELA+, ZFTA–MAML3+ (ST-1) and non-ZFTA fusion cells with or without JHU-083 (0.5, 1 μM) treatment at 96 h.

JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]

ZFTA–RELA, endogenous RELA and GAPDH in ZFTA–RELA mNSCs (left) and in EP1NS patient-derived cells (right) treated with or without JHU-083 (1, 5 and 10 μM for 96 h).

JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]

Tumour volume (fold change) in mice with MAF-1329 (ZFTA–RELA+) PDXs treated with vehicle (n = 5), JHU-083 (n = 5, 20 mg kg–1 orally, 2 doses per week), DM-Cit (n = 5, 25 mg kg−1, i.v., 3 doses per week) or a combination of JHU-083 and DM-Cit (n = 5) for 4 weeks.

JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]

JHU-083 (orally, 20 mg kg–1, 2 doses per week for 5 weeks). Representative bioluminescence images (left) and quantification (right) and haematoxylin and eosin images from spontaneous spinal metastatic tumours in mice with ZFTA–RELA mNSC xenografts treated with vehicle (n = 8), DM-Cit (n = 6) or a combination of JHU-083 and PI-103.

JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]

Western blots for RELA (relative to GAPDH) depicting changes in ZFTA-RELA fusion protein levels (purple arrow, ~83 kDa) and endogenous RELA (black arrow, 65 kDa) in ZFTA-RELA mNSCs treated with vehicle or JHU-083 (10 µM) alone (left), or in combination with 2mM Itaconate (right) at the indicated concentrations for 96h.
Cancer Cell

Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. [Abstract]

2020 Sep 14;38(3):334-349.e9. PMID: 32795401
Nat Commun

Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. [Abstract]

2024 Feb 16;15(1):1442. PMID: 38365882
Sci Adv

Liver regeneration-associated hepatocellular YAP1 activation prevents colorectal cancer liver metastasis through glutamine competition. [Abstract]

2025 Aug 22;11(34):eadw6926. PMID: 40845109
Metabolism

Liver cancer chronically exposed to palmitate acquires ferroptosis resistance via the downregulation of glutamine-driven hepcidin expression. [Abstract]

2025 Dec 17:176:156469. PMID: 41418943
Free Radic Biol Med

H1N1 influenza virus infection through NRF2-KEAP1-GCLC pathway induces ferroptosis in nasal mucosal epithelial cells. [Abstract]

2023 Aug 1:204:226-242. PMID: 37146698
Front Immunol

Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation. [Abstract]

2022 May 19:13:880262. PMID: 35663990

JHU-083 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 May 19:13:880262. [Abstract]

JHU-083 (0.3mg/kg; i.v; single) significantly decreases TUNEL-positive cells in mice, which indicates that JHU-083 ameliorates the progression of ConA-induced autoimmune hepatitis by blocking glutamine metabolism in mice.
Neuropharmacology

The glutaminase inhibitor JHU-083 mitigates cognitive dysfunction in a mouse model of post-traumatic stress disorder. [Abstract]

2025 Nov 15:279:110631. PMID: 40812515
bioRxiv

Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis. [Abstract]

2025 Sep 29:2025.09.28.674326. PMID: 41256360

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (320.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2014 mL

16.0072 mL

32.0143 mL

5 mM

0.6403 mL

3.2014 mL

6.4029 mL

10 mM

0.3201 mL

1.6007 mL

3.2014 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhu X, et al. JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. Neuropsychopharmacology. 2019 Mar;44(4):683-694. [Content Brief]

[2]. Riggle BA, et al. MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12024-E12033. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2014 mL	16.0072 mL	32.0143 mL	80.0359 mL
	5 mM	0.6403 mL	3.2014 mL	6.4029 mL	16.0072 mL
	10 mM	0.3201 mL	1.6007 mL	3.2014 mL	8.0036 mL
	15 mM	0.2134 mL	1.0671 mL	2.1343 mL	5.3357 mL
	20 mM	0.1601 mL	0.8004 mL	1.6007 mL	4.0018 mL
	25 mM	0.1281 mL	0.6403 mL	1.2806 mL	3.2014 mL
	30 mM	0.1067 mL	0.5336 mL	1.0671 mL	2.6679 mL
	40 mM	0.0800 mL	0.4002 mL	0.8004 mL	2.0009 mL
	50 mM	0.0640 mL	0.3201 mL	0.6403 mL	1.6007 mL
	60 mM	0.0534 mL	0.2668 mL	0.5336 mL	1.3339 mL
	80 mM	0.0400 mL	0.2001 mL	0.4002 mL	1.0004 mL
	100 mM	0.0320 mL	0.1601 mL	0.3201 mL	0.8004 mL

Keywords

JHU-083

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

JHU-083

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) JHU-083

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

JHU-083

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) JHU-083

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

JHU-083 Related Classifications

HY-122218 Related Classifications